Phase 3 vs Approved — Metabolic Deal Valuation Comparison
Market Analysis
The Phase 3 to Approved transition in metabolic represents a significant value inflection point. Approved deals carry a median total deal value of $14.7B compared to $7.5B at Phase 3, a 96% premium reflecting clinical de-risking. Upfront payments increase from $2.0B to $5.6B.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the deal value premium from Phase 3 to Approved in metabolic?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating